Terns Pharmaceuticals
TERN
TERN was delisted on the 4th of May, 2026.
112 hedge funds and large institutions have $415M invested in Terns Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 36 increasing their positions, 34 reducing their positions, and 17 closing their positions.
219% more call options, than puts
Call options by funds: $1.16M | Put options by funds: $362K
59% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 17
9% more funds holding
Funds holding: 103 → 112 (+9)
6% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 34
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less capital invested
Capital invested by funds: $424M → $415M (-$9.03M)
7.86% less ownership
Funds ownership: 105.68% → 97.82% (-7.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$19.1M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$14.5M |
| 3 |
Millennium Management
New York
|
+$9.43M |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
+$5.15M |
| 5 |
OCA
Octagon Capital Advisors
New York
|
+$4.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
-$29.2M |
| 2 |
Morgan Stanley
New York
|
-$18.7M |
| 3 |
B
Braidwell
Stamford,
Connecticut
|
-$15M |
| 4 |
VA
VR Adviser
New York
|
-$7.1M |
| 5 |
PA
Perceptive Advisors
New York
|
-$6.98M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
QT
126
Quantbot Technologies
New York
| – | -$29.2K | -4,498 | Closed |
|
|
FFO
127
Fortitude Family Office
Scottsdale,
Arizona
| – | -$1.95K | -300 | Closed |
|
128
Simplex Trading
Chicago,
Illinois
| – | -$1.11K | -170 | Closed |
|
|
IGWM
129
ICA Group Wealth Management
Denver,
Colorado
| – | -$519 | -80 | Closed |
|
TERN Hedge Fund Activity: Q1 2024 in Review
112 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Terns Pharmaceuticals (TERN) for Q1 2024, worth a combined $415M — down 2.1% from $424M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new TERN positions and 17 closed out — a net gain of 10 holders — while 36 added to existing stakes and 34 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $19.1M. The largest seller was Suvretta Capital Management, cutting an estimated $29.2M.
- 112 institutional investors held Terns Pharmaceuticals (TERN) as of Q1 2024, up from 103 in Q4 2023.
- Funds reported $415M of Terns Pharmaceuticals stock for Q1 2024, down 2.1% quarter-over-quarter.
- 27 funds opened new Terns Pharmaceuticals positions in Q1 2024 and 17 closed out, a net change of +10 holders.
- The largest Terns Pharmaceuticals buyer in Q1 2024 was Citadel Advisors, an estimated $19.1M added.
- The largest Terns Pharmaceuticals seller in Q1 2024 was Suvretta Capital Management, an estimated $29.2M sold.
Based on aggregated 13F filings for Q1 2024.